Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
70.33 USD   +1.91%
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Coronary Artery Disease Detection
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
66.6(c) 67.39(c) 69.33(c) 69.01(c) 70.33(c) Last
1 201 969 644 644 1 045 348 648 339 1 134 490 Volume
-2.57% +1.19% +2.88% -0.46% +1.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 899 M - -
Net income 2022 187 M - -
Net Debt 2022 - - -
P/E ratio 2022 29,2x
Yield 2022 -
Sales 2023 1 007 M - -
Net income 2023 203 M - -
Net Debt 2023 - - -
P/E ratio 2023 38,2x
Yield 2023 -
Capitalization 4 835 M 4 835 M -
Capi. / Sales 2022 5,38x
Capi. / Sales 2023 4,80x
Nbr of Employees 612
Free-Float 97,6%
More Financials
Company
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. The Company classify its commercial products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Its products in its precision diagnostics category includes... 
More about the company
Ratings of Lantheus Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about LANTHEUS HOLDINGS, INC.
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Cor..
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotra..
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer C..
AQ
09/13GE Healthcare and Lantheus Holdings Inc Announces Phase III Clinical Trial Finds [¹8F]f..
CI
09/13GE, Lantheus Say Heart Disease Tracer Trial Met Key Endpoints
DJ
09/08Insider Sell: Lantheus Holdings
MT
09/08Insider Sell: Lantheus Holdings
MT
09/01Lantheus to Present at the Wells Fargo Healthcare Conference
GL
08/25Lantheus Holdings Shares Rise After B. Riley Resumes Coverage
MT
08/25B. Riley Securities Resumes Lantheus Holdings at Buy with $102 PT, Views as 'Best Posit..
MT
08/22Insider Sell: Lantheus Holdings
MT
08/15Insider Sell: Lantheus Holdings
MT
08/11Insider Sell: Lantheus Holdings
MT
08/05SVB Securities Raises Lantheus Holdings Price Target to $110 From $100, Maintains Outpe..
MT
08/04Lantheus Reports Increase in Q2 Adjusted Net Income, Revenue; Raises 2022 Targets
MT
More news
News in other languages on LANTHEUS HOLDINGS, INC.
09/13GE : détecte mieux la maladie coronarienne
09/13Lantheus et GE Healthcare affirment qu'une étude montre que le radiotraceur TEP 18F flu..
09/13GE Healthcare et Lantheus Holdings Inc. annoncent que l'essai clinique de phase III rév..
08/25Les actions de Lantheus Holdings augmentent après la reprise de la couverture par B. Ri..
08/22Vente d'initiés : Lantheus Holdings
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
ETFs positioned on LANTHEUS HOLDINGS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Invesco S&P SmallCap Health Care ETF - USD4.64%1.24%United_States
Invesco DWA Healthcare Momentum ETF - USD3.05%2.29%United_States
First Asset Morningstar US Momentum Index E...2.25%0.00%-United_States
Invesco S&P SmallCap Momentum ETF - USD1.86%0.44%NC
HAN-GINS Indxx Healthcare Megatrend Equal W...1.1%5.80%-NC
More ETFs positioned on LANTHEUS HOLDINGS, INC.
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 70,33 $
Average target price 103,20 $
Spread / Average Target 46,7%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors